<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Major adverse effects of systemic glucocorticoids
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Major adverse effects of systemic glucocorticoids
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Major adverse effects of systemic glucocorticoids
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth G Saag, MD, MSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel E Furst, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth J Warrington, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 08, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders. Toxicity from glucocorticoids is one of the commonest causes of iatrogenic illness associated with the treatment of chronic inflammatory diseases. Recognition of these toxicities, many of which are similar to the manifestations of spontaneous (endogenous) Cushing syndrome, is valuable in their prevention and management. (See
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome"
         </a>
         .)
        </p>
        <p>
         The major adverse effects seen with systemic (oral and parenteral) glucocorticoid therapy will be reviewed here. The adverse effects resulting from the use of inhaled, topical, and intraarticular glucocorticoids; adverse effects of glucocorticoids on the immune system; clinical manifestations of endogenous glucocorticoid excess (Cushing syndrome); glucocorticoid withdrawal; and use during pregnancy are discussed in detail separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adverse effects of inhaled glucocorticoids (see
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adverse effects of topical glucocorticoids (see
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adverse effects of intraarticular glucocorticoids (see
         <a class="medical medical_review" href="/z/d/html/7977.html" rel="external">
          "Joint aspiration or injection in adults: Complications", section on 'Glucocorticoid-associated toxicity'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adverse effects of glucocorticoids on the immune system (see
         <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">
          "Glucocorticoid effects on the immune system"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diagnosis of Cushing syndrome (see
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucocorticoid withdrawal (see
         <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">
          "Glucocorticoid withdrawal"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucocorticoid use in pregnancy and lactation (see
         <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">
          "Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Glucocorticoids'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         This topic focuses on the side effects of systemic
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         in particular, as there are more data for these medications. More information about various types of steroids and equivalent doses can be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7976.html" rel="external">
          "Determinants of glucocorticoid dosing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3422657647">
         <span class="h1">
          FACTORS RELATED TO GLUCOCORTICOID TOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous toxicities, or adverse effects, have been attributed to glucocorticoids  (
         <a class="graphic graphic_table graphicRef65998" href="/z/d/graphic/65998.html" rel="external">
          table 1
         </a>
         ). However, other factors may also contribute to the development of adverse effects in a given patient, such as the nature and severity of the underlying disease being treated and the other concurrent medications. Estimates of the frequency and severity of adverse effects, as well as the respective dose and duration of therapy that may result in adverse effects, are also limited by the modest number of prospective studies and the very few randomized controlled trials that address this question with high methodologic rigor.
        </p>
        <p class="headingAnchor" id="H24131064">
         <span class="h2">
          Mechanisms of adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids used in chronic disease (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         ) do not have significant mineralocorticoid, androgenic, or estrogenic activity; thus, their major adverse effects result from inhibition of hypothalamic-pituitary-adrenal function and the development of iatrogenic Cushing syndrome. (See
         <a class="medical medical_review" href="/z/d/html/124.html" rel="external">
          "Pharmacologic use of glucocorticoids", section on 'Complications of chronic use'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome"
         </a>
         .)
        </p>
        <p>
         Differences in glucocorticoid bioavailability and receptor activation influence the efficacy and toxicity of different glucocorticoids. Genetic polymorphisms in the glucocorticoid receptor and glucocorticoid metabolism can therefore impact glucocorticoid effects. This variability helps explain the differential resistance to therapy and toxicities among patients [
         <a href="#rid1">
          1-4
         </a>
         ]. Mechanisms involved in the adverse effects of glucocorticoids are described in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7976.html" rel="external">
          "Determinants of glucocorticoid dosing"
         </a>
         .)
        </p>
        <p>
         Prolonged effects of glucocorticoid exposure, such as atrophy of cells in the anterior pituitary and adrenal gland, are caused in part by the nonspecific effects of glucocorticoids on cellular function [
         <a href="#rid5">
          5
         </a>
         ]. Once cell atrophy occurs, full recovery from glucocorticoid effects may take months or even years after stopping the medication.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Glucocorticoid dose and duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several retrospective reviews have shown that long-term glucocorticoid use, even in low doses, is a significant independent predictor of numerous adverse effects and that the risk is both dose- and duration-dependent [
         <a href="#rid6">
          6-9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2307812160">
         <span class="h3">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The daily dose of glucocorticoid is a key factor in toxicity, with higher doses carrying a higher risk of adverse effects [
         <a href="#rid6">
          6,7,9
         </a>
         ]. A study of 112 patients with rheumatoid arthritis (RA) found that the average daily
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose was the strongest predictor of a serious adverse effect potentially attributable to glucocorticoid therapy, even after adjustment for RA disease severity (odds ratio [OR] 4.5 for 5 to 10 mg and 32.3 for 10 to 15 mg)  (
         <a class="graphic graphic_figure graphicRef53432" href="/z/d/graphic/53432.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. The preselected adverse effects included in the analysis were fracture, serious infections, gastrointestinal bleed or ulcer, and cataracts.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Very low doses
         </strong>
         – There are some data that suggest that very low doses of glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         &lt;5 mg/day) are associated with fewer adverse effects [
         <a href="#rid10">
          10,11
         </a>
         ]. While randomized trial data are limited, a double-blind placebo-controlled trial randomized patients over age 65 years with RA to an add-on of 5 mg/day of
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         for a two-year period [
         <a href="#rid12">
          12
         </a>
         ]. At least one adverse effect was noted in 60 percent of patients on prednisone versus 49 percent of patients on placebo, giving an increased adjusted relative risk of 1.24 (95% CI 1.04). The largest difference between groups was in mild to moderate infections requiring treatment, and other glucocorticoid-specific adverse effects were rare. However, other studies have suggested adverse effects even at low doses, including suppression of the hypothalamic-pituitary-adrenal (HPA) axis in patients who were on under 5 mg/day of prednisone for less than four weeks and development of cataracts [
         <a href="#rid6">
          6,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Linear and threshold patterns of adverse effects
         </strong>
         – Different patterns dose-related adverse glucocorticoid effects have been described, including a "linear" relationship (increasing frequency with increasing dose) and a "threshold" effect (effect more common above a certain dose). A large retrospective analysis, which included data from 1066 patients with RA on glucocorticoids for more than six months, observed a linear pattern for Cushingoid phenotype, ecchymosis, leg edema, fungal infections, parchment-like skin, shortness of breath, and sleep disturbance [
         <a href="#rid6">
          6,14
         </a>
         ]. A threshold pattern was seen for glaucoma, depression, and elevated blood pressure at doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         greater than 7.5 mg/day and for weight gain and epistaxis at doses of prednisone greater than 5 mg/day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High "pulse" dose
         </strong>
         – Glucocorticoids are sometimes given as high-dose "pulse" infusions (eg, 1 g/day of intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         for multiple days) in an attempt to rapidly control severe manifestations of autoimmune or other rheumatic diseases. Such dosing may cause more prominent adverse effects including increased appetite and weight gain, gastritis, insomnia, and mood changes. It can also cause bradycardia and rarely other serious cardiovascular toxicities [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="local">
          'Cardiovascular effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3898373693">
         <span class="h3">
          Duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Longer duration of glucocorticoid therapy and therefore higher cumulative doses are associated with adverse effects [
         <a href="#rid6">
          6-9
         </a>
         ]. However, shorter-term glucocorticoid use may also be associated with serious adverse effects, particularly with higher doses.
        </p>
        <p>
         It is unclear if there is a threshold for duration of glucocorticoid therapy at which adverse effects become more prominent. For example, patients may experience iatrogenic adrenal insufficiency regardless of the duration of therapy, although it is more common with longer courses [
         <a href="#rid16">
          16
         </a>
         ]. In our opinion, taking a week of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , even at higher doses, is unlikely to suppress the HPA axis; however, this is based on limited data. A study of a short course of moderate-dose prednisone (40 mg/day, tapering off over seven days) did not show HPA axis suppression [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Several studies describe a potential link between serious adverse effects and relatively short-term glucocorticoid use. These studies used nationwide datasets of private insurance claims, meaning important limitations include potential misclassification of diagnoses in large databases, lack of accounting for comorbidities and concomitant medications, and inability to control for other time-varying factors that could have been differentially distributed between the risk and baseline periods.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective cohort study and self-controlled case series using a nationwide dataset of private insurance claims in the United States assessed the risk of three adverse effects (sepsis, venous thromboembolism [VTE], and fracture) in 327,452 adults younger than 65 years of age who received at least one short-term (&lt;30 days) outpatient prescription over a three-year period [
         <a href="#rid18">
          18
         </a>
         ]. The glucocorticoid dose varied, with prepackaged
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         accounting for almost half of prescriptions (equivalent to 105 mg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         over six days) and doses equivalent to &lt;17.5 mg/day of prednisone accounting for only 6.3 percent of prescriptions. Within 30 days of drug initiation, there were increases in the rates of sepsis (incidence rate ratio [IRR] 5.30, 95% CI 3.80-7.41), VTE (IRR 3.33, 95% CI 2.78-3.00), and fracture (IRR 1.887, 95% CI 1.69-2.07), which then decreased over the subsequent 31 to 90 days. The absolute risks of each of the adverse effects was low.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another large case-controlled case series using a nationwide dataset of private insurance claims included 2,623,327 persons aged 20 to 64 years who had received a single
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         burst for 14 days or fewer [
         <a href="#rid19">
          19
         </a>
         ]. Within the 5 to 30 days after glucocorticoid initiation, rates of gastrointestinal bleeding (IRR 1.80, 95% CI 1.75-1.84), sepsis (IRR 1.99, 95% CI 1.70-2.32), and heart failure (IRR 2.37, 95% CI 2.13-2.63) increased, but then the risk attenuated during the subsequent 31 to 90 days.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          ORGAN-BASED TOXICITY OF SYSTEMIC GLUCOCORTICOIDS
         </span>
        </p>
        <p class="headingAnchor" id="H2718697513">
         <span class="h2">
          Delayed presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some adverse effects, such as accelerated reductions in bone mineral density or early cataracts, may be largely asymptomatic until later manifestations develop that require medical attention (eg, acute vertebral collapse, cataract requiring surgical extraction).
        </p>
        <p class="headingAnchor" id="H2390219185">
         <span class="h2">
          Reversibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many glucocorticoid toxicities are at least partially reversible over time with glucocorticoid discontinuation, with the exception of cataracts, a potential acceleration in atherosclerotic vascular disease, bone effects (osteoporosis and osteonecrosis), and possible long-term effects on linear growth in children. (See
         <a class="local">
          'General treatment considerations and monitoring'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4290750410">
         <span class="h2">
          Specific systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids have numerous and variable toxicities  (
         <a class="graphic graphic_table graphicRef65998" href="/z/d/graphic/65998.html" rel="external">
          table 1
         </a>
         ). These adverse effects range from those that are temporary but challenging for patients (eg, insomnia) to those that are life threatening (eg, serious infections).
        </p>
        <p class="headingAnchor" id="H1350453702">
         <span class="h3">
          Metabolic and endocrine effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypothalamic-pituitary-adrenal axis suppression
         </strong>
         – Administration of exogenous glucocorticoids, particularly when given in divided doses, can suppress the hypothalamic-pituitary-adrenal (HPA) axis. Abrupt cessation or rapid withdrawal of glucocorticoids in such patients may cause symptoms of adrenal insufficiency. The approach to withdrawal of glucocorticoids, HPA axis suppression, and the clinical manifestations of adrenal insufficiency are presented separately [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">
          "Glucocorticoid withdrawal"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperglycemia
         </strong>
         – The mechanism by which glucocorticoids cause hyperglycemia is multifactorial, including augmentation of hepatic gluconeogenesis, inhibition of glucose uptake in adipose tissue, and alteration of receptor and post-receptor functions [
         <a href="#rid1">
          1,21-23
         </a>
         ]. It is also possible that some underlying disorders for which glucocorticoids are used, such as rheumatoid arthritis (RA), may independently predispose to a higher rate of glucose intolerance [
         <a href="#rid24">
          24
         </a>
         ]. Monitoring for hyperglycemia is discussed below. (See
         <a class="local">
          'Monitoring and treatment of adverse effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients without preexisting diabetes mellitus
         </strong>
         – Patients who do not have preexisting diabetes may develop hyperglycemia and/or diabetes mellitus while taking glucocorticoids. A meta-analysis of studies involving glucocorticoids indicated that hyperglycemia and diabetes were discovered in 23 and 19 percent of patients respectively [
         <a href="#rid25">
          25
         </a>
         ]. Glucocorticoid-induced hyperglycemia improves with reduction in the dose of glucocorticoid and usually reverses when the medication is stopped, although some patients develop persistent diabetes [
         <a href="#rid26">
          26,27
         </a>
         ]. New-onset hyperglycemia or, rarely, a nonketotic hyperosmolar state or diabetic ketoacidosis can develop without warning in patients with early subclinical diabetes or glucose intolerance [
         <a href="#rid28">
          28-30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         More commonly, systemic glucocorticoids can cause a dose-dependent, usually mild, increase in fasting glucose levels and a greater increase in postprandial glucose levels in patients without preexisting diabetes mellitus. In a case-control study of Medicaid recipients, the relative risk of developing hyperglycemia requiring glucose-lowering therapy increased progressively with increasing glucocorticoid dose [
         <a href="#rid30">
          30
         </a>
         ]. The relative risk increased from 1.8 in patients treated with the equivalent of less than 10 mg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         to 10.3 in those with the equivalent of more than 30 mg/day of prednisone [
         <a href="#rid30">
          30
         </a>
         ]. Risk factors for new-onset hyperglycemia during glucocorticoid therapy are thought to be the same as those for other patients, including a family history of diabetes, increased age, obesity, and a history of gestational diabetes [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/109527.html" rel="external">
          "Comorbidities that impact management of osteoarthritis", section on 'Diabetes mellitus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with preexisting diabetes mellitus
         </strong>
         – Patients with preexisting diabetes mellitus or glucose intolerance exhibit higher blood glucose levels while taking glucocorticoids, leading to increased difficulty with glycemic control.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3688998844">
         <span class="h3">
          Dermatologic effects and appearance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many clinically relevant adverse effects of glucocorticoids on the skin and appearance have been observed even at lower doses, including Cushingoid features, weight gain, skin thinning, striae, ecchymoses, acne, mild hirsutism, and facial erythema.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cushingoid features
         </strong>
         – The development of Cushingoid features (redistribution of body fat with truncal obesity, buffalo hump, and moon face) and weight gain are dose- and duration-dependent and can develop within the first two months of therapy  (
         <a class="graphic graphic_picture graphicRef77261" href="/z/d/graphic/77261.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef82478" href="/z/d/graphic/82478.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef82114" href="/z/d/graphic/82114.html" rel="external">
          picture 3
         </a>
         ). A Cushingoid appearance is uncommon at doses below the physiologic glucocorticoid-replacement range but can develop even with low-dose therapy. Cushingoid features showed a linear increase in frequency with dose rather than a threshold effect. In an observational study of 779 patients RA who received &lt;5, 5 to 7.5, and &gt;7.5 mg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or equivalent, Cushingoid features were observed in 4.3, 15.8, and 24.6 percent of patients, respectively [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome", section on 'Progressive obesity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Weight gain
         </strong>
         – Weight gain is commonly reported among patients taking glucocorticoids, and was the most common self-reported adverse effect (70 percent of patients) in a survey of 2167 patients taking long-term glucocorticoids (mean
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         equivalent dose ± standard deviation [SD] of 16±14 mg/day for ≥60 days) [
         <a href="#rid9">
          9
         </a>
         ]. Studies have noted weight gain is more common among patients with RA taking 5 mg of prednisone or more daily [
         <a href="#rid6">
          6
         </a>
         ]. The amount of weight gained can vary, but in an analysis of four prospective trials of glucocorticoids in patients with RA, the use of 5 to 10 mg/day of prednisone or equivalent over two years was associated with an increase of mean body weight of 4 to 8 percent [
         <a href="#rid10">
          10
         </a>
         ]. Factors that may contribute to increased weight include an increased appetite, which is a common side effect of glucocorticoid therapy, and an increase in food intake for symptomatic relief in patients with gastropathy or peptic ulcer disease [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin thinning, striae, and ecchymoses
         </strong>
         – Among the most common toxicities attributable to glucocorticoids are skin thinning, striae, and ecchymoses, which can occur even at low doses and are similar to those noted in Cushing syndrome  (
         <a class="graphic graphic_picture graphicRef67682" href="/z/d/graphic/67682.html" rel="external">
          picture 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef65564" href="/z/d/graphic/65564.html" rel="external">
          picture 5
         </a>
         ) [
         <a href="#rid10">
          10,33
         </a>
         ]. A large observational study with patient-reported data from patients with RA on glucocorticoids for at least six months reported rates of parchment-like skin and ecchymoses in 10 and 17 percent, respectively [
         <a href="#rid6">
          6
         </a>
         ]. The prevalence of these effects also increased with higher doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         . In a prospective study with 80 patients, skin changes were observed in 46 percent of patients treated for three months with prednisone at doses greater than 20 mg/day [
         <a href="#rid33">
          33
         </a>
         ]. The ecchymoses or purpura associated with glucocorticoid use often affects the sun-exposed areas of the dorsum of the hand and forearm and is not accompanied by palpable swelling (see
         <a class="medical medical_review" href="/z/d/html/15255.html" rel="external">
          "Photoaging", section on 'Photoaging in individuals with phototypes I to IV'
         </a>
         ). Striae develop often due to a combination of skin thinning and weight gain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While evidence is limited to support any intervention to prevent skin manifestations, patients may benefit from photoprotective measures (eg, use of sunscreen with sun protection factor [SPF]) and keeping the skin moisturized. Although there is some reported success for various creams, lasers, and microabrasion, no large well-conducted studies have been done and no specific recommendations can be made to prevent or treat striae associated with glucocorticoid use [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – Other side effects such as acne (occurring in 2 to 19 percent of patients), hirsutism (occurring in 5 to 8 percent of patients), and facial swelling may occur but are reversible when the glucocorticoids are stopped. The treatment of these conditions is the same as for people who are not taking glucocorticoids. (See
         <a class="medical medical_review" href="/z/d/html/42.html" rel="external">
          "Acne vulgaris: Overview of management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1589.html" rel="external">
          "Removal of unwanted hair"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Cardiovascular effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoid use has been associated with a variety of adverse cardiovascular effects including fluid retention, hypertension, premature atherosclerotic disease, and arrhythmias. Cardiovascular disease risk is dose-dependent and may be low or absent in patients on low-dose glucocorticoid therapy [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluid retention
         </strong>
         – Higher-dose glucocorticoids may promote fluid retention, which is of particular concern to patients with underlying heart or kidney disease. This is not a problem in patients without those comorbidities because of the phenomenon of mineralocorticoid escape that prevents progressive fluid overload. (See
         <a class="medical medical_review" href="/z/d/html/140.html" rel="external">
          "Pathophysiology and clinical features of primary aldosteronism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertension
         </strong>
         – Hypertension is a known adverse effect of glucocorticoids and has been observed in up to 20 percent of patients with iatrogenic Cushing syndrome [
         <a href="#rid36">
          36
         </a>
         ]. It is a dose-related adverse effect and is unlikely in patients receiving low doses of glucocorticoids (eg, 10 mg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ) [
         <a href="#rid6">
          6,28,37-39
         </a>
         ]. Based on pooled data from trials involving patients with RA, blood pressure was not significantly higher among patients who were randomized to receive low-dose glucocorticoids (equivalent to 7.5 mg/day or less of prednisone) for two years compared with those receiving placebo [
         <a href="#rid40">
          40
         </a>
         ]. In patients taking low doses, significant hypertension may be better explained by age and initial blood pressure than by the glucocorticoids themselves [
         <a href="#rid41">
          41
         </a>
         ]. The mechanism by which glucocorticoid therapy can raise the blood pressure is not well understood [
         <a href="#rid42">
          42,43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome", section on 'Hypertension'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Premature atherosclerotic disease
         </strong>
         – Glucocorticoid use has been associated with increased rates of myocardial infarction, stroke, heart failure, and all-cause mortality, at least at doses greater than 5 to 7.5 mg/day [
         <a href="#rid35">
          35,44
         </a>
         ]. However, rheumatic disease may be an independent risk factor for premature atherosclerotic disease, and it is unclear to what extent this may confound current studies. The association between glucocorticoid use and atherosclerotic disease is less clear when studies are limited to populations receiving glucocorticoid for inflammatory disorders [
         <a href="#rid39">
          39,45-47
         </a>
         ]. In a large longitudinal cohort study of over 12,000 patients with rheumatoid arthritis, the relationship between glucocorticoid exposure and incident major adverse cardiovascular events (MACE) was assessed over a mean follow-up time of 8.7 years [
         <a href="#rid48">
          48
         </a>
         ]. Patients taking &gt;5 mg/day of
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         had a higher risk of MACE compared with patients not taking glucocorticoids (adjusted hazard ratio [HR] 2.20 [95% CI, 1.87-2.37]), and the risk increased with intermediate-term (up to 180 days) and long-term (&gt;180 days) use. The risk of MACE was not significantly different for patients taking under 5 mg of prednisolone compared with patients not taking glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arrhythmias
         </strong>
         – An association of glucocorticoid use with risk of atrial fibrillation and flutter has been reported in several studies [
         <a href="#rid49">
          49-51
         </a>
         ]. In a population-based case-control study, current glucocorticoid use was more common among 20,221 patients with atrial fibrillation or flutter compared with the 202,130 population controls (6.4 versus 2.6 percent) [
         <a href="#rid51">
          51
         </a>
         ]. Currently using glucocorticoids was associated with a significant increased risk of atrial fibrillation or flutter, compared with never having used glucocorticoids (adjusted odds ratio [OR] 1.9). Risk was increased for new users and long-term users but not for former users (ORs 3.6, 1.7, and 1.0, respectively) and was unrelated to whether or not pulmonary or cardiovascular disease was present. Sinus bradycardia has also been reported with glucocorticoids, especially with higher "pulse" dosing [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Serious adverse cardiovascular toxicities, including sudden death, have been reported in occasional patients who have been given pulse infusions of glucocorticoids (eg, 1 g/day of
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         for multiple infusions) [
         <a href="#rid15">
          15
         </a>
         ]. In many of these cases, however, it was difficult to determine whether this adverse effect was more likely attributable to glucocorticoids or to the underlying disorder necessitating the therapy. Thus, cardiac monitoring is indicated in patients with significant cardiac disease who are treated with pulse glucocorticoid therapy, especially those on diuretics, the use of which may also be associated with electrolyte disturbances such as hypokalemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary emboli and venous thrombotic events
         </strong>
         – Limited observational data suggest that glucocorticoids may be associated with an increased risk of pulmonary emboli and venous thromboembolism (VTE).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a retrospective study in the Netherlands that compared 648 patients using chronic glucocorticoids for asthma with the general population, both severe asthma and oral glucocorticoids appeared to be independent risk factors for pulmonary emboli (HR 3.33, 95% CI 1.16-9.93 and 2.82, 95% CI 1.09-7.30, respectively) [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Two large retrospective studies using national databases in the United States identified increased risk of VTE. A cohort study and self-controlled case series using private insurance claims and assessed the risk of VTE in 27,452 adults using short-term (ie, less than 30 days) glucocorticoid use over three years. Within 30 days of glucocorticoid use, there was an increased rate of VTE (incidence rate ratio [IRR] 3.33, 95% CI 2.78-3.00), which then decreased over the subsequent 31 to 90 days [
         <a href="#rid18">
          18
         </a>
         ]. Another analysis of 94,620 neurosurgical patients found that glucocorticoids were associated with an increased risk of pulmonary emboli (OR 1.47, 1.13-1.90) and deep vein thrombosis (OR 1.55, 1.28-1.87) within 30 days of surgery [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Possible hyperlipidemia
         </strong>
         – The effect of glucocorticoids on atherosclerotic vascular disease is thought to be mediated in part by elevated nonfunctional lipoprotein levels [
         <a href="#rid55">
          55
         </a>
         ]. However, studies analyzing the impact of glucocorticoids on hyperlipidemia have had mixed results and interpretation is complicated by the difficulty of distinguishing effects due to disease activity from effects directly related to the medications themselves [
         <a href="#rid56">
          56
         </a>
         ]. One large observational study concluded that glucocorticoid use was associated with a more favorable lipid profile in older adults (≥60 years) [
         <a href="#rid57">
          57
         </a>
         ]. In another report, moderate- to low-dose
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (20 mg/day tapered to 5 mg/day over three months) had no significant adverse effect on lipoprotein levels if other risk factors were taken into account [
         <a href="#rid58">
          58
         </a>
         ]. Studies in patients with systemic lupus erythematosus (SLE) have indicated that the adverse effects of glucocorticoids on lipid profiles are dose-dependent, occurring only at prednisone doses greater than 10 mg/day [
         <a href="#rid59">
          59-61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Gastrointestinal effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Upper gastrointestinal tract complications
         </strong>
         – Glucocorticoids increase the risk for adverse gastrointestinal effects, such as gastritis, ulcer formation, and gastrointestinal bleeding. The estimated relative risks of glucocorticoids alone for gastrointestinal adverse effects vary from 1.1 (not significant) to 1.5 (marginally significant) [
         <a href="#rid62">
          62,63
         </a>
         ]. However, the combination of glucocorticoids and nonsteroidal antiinflammatory drugs (NSAIDs) results in a synergistic increase in the incidence of gastrointestinal events as shown by the following findings from two meta-analyses:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Glucocorticoid use is associated with a nearly twofold increased risk of a gastrointestinal adverse effect among patients also taking NSAIDs when compared with those who use NSAIDs alone [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The use of NSAIDs and glucocorticoids is associated with a fourfold increased risk of a gastrointestinal adverse effect compared with nonuse of either drug [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether substitution of a selective cyclooxygenase (COX) 2 inhibitor for a nonselective NSAID would lower this risk is unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lower gastrointestinal tract complications
         </strong>
         – Potential complications of glucocorticoid use include visceral perforation [
         <a href="#rid66">
          66-68
         </a>
         ]. Glucocorticoids may also mask the symptoms of serious gastrointestinal disease, an effect that may partially account for the increased risk of perforated sigmoid diverticular abscess associated with their use [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Given the apparent association of
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         with lower gastrointestinal tract perforations, the question has been raised as to whether the concomitant use of glucocorticoids can further increase this risk. In one study using registry data of patients on biologic agents for RA, the risk of lower intestinal perforation increased by 1.28 (95% CI 1.18-1.38) for each 5 mg/day increase in
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose when added to tocilizumab [
         <a href="#rid65">
          65
         </a>
         ]. In another cohort study that included 167,113 patients with RA, the use of tocilizumab, and possibly tofacitinib, was associated with an increased risk of gastrointestinal perforation [
         <a href="#rid69">
          69
         </a>
         ]. The risk of gastrointestinal perforation appeared to be further increased with prednisone use of more than 7.5 mg/day (HR 2.29, 95% CI 1.39-3.78).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatic steatosis
         </strong>
         – Glucocorticoid use has been associated with hepatic steatosis (fatty liver) that can rarely lead to cirrhosis [
         <a href="#rid70">
          70-73
         </a>
         ]. This is more common when the patient is obese.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pancreatitis
         </strong>
         – Although glucocorticoids have also been implicated in causing acute pancreatitis [
         <a href="#rid74">
          74-76
         </a>
         ], their role remains uncertain. In a study including 6161 patients with acute pancreatitis each matched with 10 controls, the multivariable-adjusted risk of acute pancreatitis was increased among current glucocorticoid users compared with nonusers (OR 1.53, 95% CI 1.27-1.84) [
         <a href="#rid76">
          76
         </a>
         ]. Other studies, particularly in patients with SLE, have shown that pancreatitis is caused by the disease rather than the drugs and that glucocorticoids may be beneficial therapeutically [
         <a href="#rid77">
          77,78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5640.html" rel="external">
          "Etiology of acute pancreatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Bone and muscle effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osteoporosis
         </strong>
         – Osteoporosis is a well-known and exceptionally common adverse effect of glucocorticoid use and is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">
          "Clinical features and evaluation of glucocorticoid-induced osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osteonecrosis
         </strong>
         – Osteonecrosis (avascular or ischemic necrosis of bone) has also been associated with glucocorticoid use, particularly with high doses of glucocorticoids. Glucocorticoid-induced osteonecrosis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/122049.html" rel="external">
          "Clinical manifestations and diagnosis of osteonecrosis (avascular necrosis of bone)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myopathy
         </strong>
         – Myopathy is an infrequent complication of glucocorticoid therapy and is typical seen at higher doses. It presents as painless proximal motor weakness in both the upper and lower extremities. Glucocorticoid-induced myopathy is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5171.html" rel="external">
          "Glucocorticoid-induced myopathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More acute and severe weakness noted in critically ill patients has been attributed at least in part to the use of glucocorticoids. Variously referred to as critical illness myopathy and acute quadriplegic myopathy, it has also been suspected to be due to an interaction between glucocorticoids and neuromuscular blocking agents. This is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5144.html" rel="external">
          "Neuromuscular weakness related to critical illness", section on 'Critical illness myopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Neuropsychiatric effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids induce a range of psychiatric and cognitive symptoms, which depend upon dose and duration of therapy [
         <a href="#rid33">
          33,79
         </a>
         ]. In most patients, these symptoms are mild and reversible, but emotional lability, hypomania, mania, depression, psychosis, delirium, confusion, or disorientation (which are more common in older patients), insomnia, motor restlessness, and cognitive changes including memory deficits may occur [
         <a href="#rid80">
          80,81
         </a>
         ]. Older patients may be at higher risk for depression, mania, delirium, confusion, or disorientation [
         <a href="#rid81">
          81
         </a>
         ]. The risk of developing a given neuropsychiatric effects following glucocorticoid therapy may be increased among patients with a past history of neuropsychiatric disorders [
         <a href="#rid81">
          81
         </a>
         ]. We describe several conditions in more depth below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep disturbances
         </strong>
         – Patients commonly report sleep disturbances [
         <a href="#rid82">
          82
         </a>
         ]. Cortisol excretion is lowest between 4 and 8 PM, so logic dictates that using glucocorticoids during that time has the highest probability of disrupting the diurnal rhythm [
         <a href="#rid83">
          83
         </a>
         ]. Sleep disturbances can often be minimized by taking a daily dose on awakening in the morning and avoiding split daily dosing when possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mood disorders
         </strong>
         – Patients receiving glucocorticoids often experience an improved sense of wellbeing within several days of starting the medications; mild euphoria or anxiety may also be seen [
         <a href="#rid80">
          80,84,85
         </a>
         ]. Hypomanic reactions and activated states are more common early in therapy than is depression, but the prevalence of depression is greater in patients on more longstanding therapy, even on low to moderate doses [
         <a href="#rid80">
          80,84,86
         </a>
         ]. Patients with a family history of depression or alcoholism are at increased risk for affective diseases when given glucocorticoids [
         <a href="#rid87">
          87
         </a>
         ]. An increased risk of panic disorder may be present [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More severe mood disorder symptoms can occur within a few days in patients receiving high doses of glucocorticoids. As an example, in one prospective but uncontrolled study of 50 patients receiving 75 to 100 mg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or equivalent for greater than a week for various ophthalmologic indications, hypomanic and depressive symptoms were induced in approximately 30 and 10 percent of patients respectively by the end of one week [
         <a href="#rid88">
          88
         </a>
         ]. No patient developed dementia or became delirious or overtly psychotic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There may be an increased risk of suicidal behavior in patients taking glucocorticoid use, especially among younger patients. In a retrospective analysis involving 372,696 adult patients in general practices in the United Kingdom, there was a five- to sevenfold increased risk of completed or attempted suicide among patients receiving glucocorticoids, compared with patients with the same diagnoses who were not receiving such medications; however, the absolute risk was extremely low, approximating 0.1 cases per 100 patient-years of therapy [
         <a href="#rid81">
          81
         </a>
         ]. The observational nature of the study and potential for unknown confounding variables limit study interpretation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychosis
         </strong>
         – Psychosis can occur but does so almost exclusively at doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         above 20 mg/day given for a prolonged period [
         <a href="#rid10">
          10,89,90
         </a>
         ]. Approximately 10 percent of patients have persistent symptoms that may require treatment despite reduction of glucocorticoid dose [
         <a href="#rid91">
          91
         </a>
         ]. Response to antipsychotic drug treatment is typically complete and occurs within two weeks of initiation of neuroleptics.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hypoalbuminemia may be a risk factor for glucocorticoid-induced psychosis in patients with SLE [
         <a href="#rid92">
          92
         </a>
         ]. Patients with SLE who are on higher glucocorticoid doses present a particular problem since it is often difficult to differentiate psychosis due to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         from neuropsychiatric lupus, which may require high-dose glucocorticoid treatment. (See
         <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">
          "Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17193.html" rel="external">
          "Psychosis in adults: Epidemiology, clinical manifestations, and diagnostic evaluation", section on 'Medical and substance/medication-related causes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Memory impairment
         </strong>
         – Memory impairment has been associated with glucocorticoid use. As an example, a cohort study of 115 patients with RA found that glucocorticoid use was a predictor of poor cognition when controlling for depression, disease severity and duration, and C-reactive protein level [
         <a href="#rid93">
          93
         </a>
         ]. Another report found that patients treated with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         doses of 5 to 40 mg/day for at least one year had a partial loss of explicit memory; older patients were more susceptible to memory impairment with less protracted treatment [
         <a href="#rid79">
          79,94
         </a>
         ]. The effect on memory began as early as three months after the initiation of therapy. Approximately 1 percent of patients may be affected by more severe and persisting cognitive disturbances beginning during glucocorticoid treatment; this has been termed steroid dementia. In some patients, this condition may not remit for between 1 and 11 months after discontinuing the medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other symptoms
         </strong>
         – Akathisia can occur even in patients taking low doses. Rare cases of pseudotumor cerebri have been associated with glucocorticoid use, although higher doses are often effective in alleviating this generally self-limiting disorder [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2248687641">
         <span class="h3">
          Ophthalmologic effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of both cataracts and glaucoma is increased in patients on glucocorticoids and is dose-related [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6904.html" rel="external">
          "Cataract in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6909.html" rel="external">
          "Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6903.html" rel="external">
          "Angle-closure glaucoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cataracts
         </strong>
         – Cataracts commonly occur after prolonged glucocorticoid use, even at very low doses. They are usually bilateral and develop slowly. They typically occur in a posterior subcapsular location and can usually be distinguished from senile cataracts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There may be no minimal safe dose with respect to the risk of cataract formation, although risk is dose- and time-dependent and is more common with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         doses greater than 10 mg/day or with medications that have been administered for more than one year [
         <a href="#rid96">
          96-98
         </a>
         ]. In a study that evaluated 122 patients with RA taking a mean dose of prednisone of 8 mg/day for an average of 6.9 years, 29 percent developed cataracts compared with 18 percent of matched controls [
         <a href="#rid8">
          8
         </a>
         ]. Another study of patients with RA receiving a mean dose of 6 mg/day of prednisone for a mean of six years also found cataracts more common in patients on glucocorticoids than in patients not using prednisone (15 versus 4.5 percent) [
         <a href="#rid7">
          7
         </a>
         ]. Another study indicated that even prednisone doses &lt;5 mg/day were associated with cataracts [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased intraocular pressure
         </strong>
         – Glucocorticoids can also increase intraocular pressure. This form of glaucoma occurs most commonly in patients who use glucocorticoid eye drops. However, it has been observed in chronic and, to a lesser extent, acute systemic glucocorticoid use, particularly among those with antecedent risk for glaucoma and those taking doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ≥7.5 mg/day [
         <a href="#rid6">
          6,99
         </a>
         ]. This risk of glaucoma associated with glucocorticoid use is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15695.html" rel="external">
          "Open-angle glaucoma: Treatment", section on 'Glucocorticoids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exophthalmos
         </strong>
         – Exophthalmos and swelling of the lids and ocular muscles are rare ophthalmologic complications of glucocorticoids [
         <a href="#rid100">
          100,101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central serous chorioretinopathy
         </strong>
         – A rare adverse effect of systemic, local, or even topical use of glucocorticoids is central serous chorioretinopathy [
         <a href="#rid102">
          102-104
         </a>
         ]. Chorioretinopathy is associated with edema formation that can separate the retina from the choroid. Reduction of glucocorticoid dose is the most important element of treatment if it can be done without causing a dangerous exacerbation of the disease that is being treated with the glucocorticoids [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3496124680">
         <span class="h3">
          Immune system effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic glucocorticoids have many effects upon innate and acquired immunity that predispose to infection, resulting in a dose-dependent increase in the risk of infection, especially with common bacterial, viral, and fungal pathogens. In addition, patients taking glucocorticoids may not manifest signs and symptoms of infection as clearly, due to the inhibition of cytokine release and associated reduction in inflammatory and febrile responses. This can impair early recognition of infection. As with other glucocorticoid adverse effects, it is challenging to differentiate how the risk of infection is mediated or independently influenced by other patient factors including the underlying disorder, other comorbidities, patient age and functional status, the presence of concomitant immunosuppressive therapies, lymphopenia, and hospitalizations [
         <a href="#rid106">
          106,107
         </a>
         ]. Newer data suggest that even low-dose steroids may increase infection risk [
         <a href="#rid108">
          108
         </a>
         ]. The risk of infection with glucocorticoid therapy and the mechanisms underlying such risk are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">
          "Glucocorticoid effects on the immune system"
         </a>
         .)
        </p>
        <p>
         Similar to many other adverse effects of glucocorticoids, infection risk can increase even with small doses taken for prolonged periods of time (eg, 5 mg/day taken over two years), and cumulative exposure is important, as illustrated in studies of patient with RA [
         <a href="#rid12">
          12,109
         </a>
         ].
        </p>
        <p>
         Inhaled and topical glucocorticoids are usually not implicated in increased risk of systemic infections, in contrast to the effects seen with systemic agents. The side effects of inhaled and topical glucocorticoids are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          Other effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic effects
         </strong>
         – Pharmacologic doses of glucocorticoids often result in an increased white blood cell count (leukocytosis) that is due primarily to an increase in neutrophils (neutrophilia). This phenomenon is due to a decreased proportion of neutrophils that are adhering to the endothelium. This effect of glucocorticoids is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8381.html" rel="external">
          "Approach to the patient with neutrophilia", section on 'Medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effect on serum creatinine
         </strong>
         – Glucocorticoid use may increase plasma creatinine without impacting the glomerular filtration rate [
         <a href="#rid110">
          110
         </a>
         ]. Serum cystatin C does not appear to be affected [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tooth pain
         </strong>
         – Dental hypersensitivity-like tooth pain associated with glucocorticoids has been described and was reported in almost 18 percent of patients in one study [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4156166684">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1281459893">
         <span class="h2">
          Young children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Growth impairment is commonly seen in children receiving glucocorticoids. The effect is most pronounced with daily therapy, may be less with an alternate-day regimen, and can occur with inhaled glucocorticoids. The effects of glucocorticoid therapy on growth in children are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5832.html" rel="external">
          "Causes of short stature", section on 'Glucocorticoid therapy'
         </a>
         .)
        </p>
        <p>
         Children are more susceptible to cataract formation compared with adults. (See
         <a class="medical medical_review" href="/z/d/html/6270.html" rel="external">
          "Cataract in children", section on 'Glucocorticoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3621940572">
         <span class="h2">
          Menstruating females
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some female patients who are menstruating may report delayed, irregular, heavier, or lighter menstruation [
         <a href="#rid33">
          33
         </a>
         ]. This can happen even after a one-time injection of glucocorticoids [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3598344855">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risks associated with glucocorticoid use during pregnancy and lactation are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">
          "Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Glucocorticoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H343418">
         <span class="h1">
          GENERAL TREATMENT CONSIDERATIONS AND MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         We try to limit the adverse effects of glucocorticoids by taking the following steps:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use the lowest dose of glucocorticoids for the shortest period of time needed to achieve the treatment goals
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assess for preexisting comorbid conditions that may increase risk, and optimize the management of those conditions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use preventative interventions when available (ie, immunizations to prevent infections, exercise and treatments to prevent osteoporosis)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitor patients for adverse effects and pursue corrective interventions when possible  (
         <a class="graphic graphic_table graphicRef143142" href="/z/d/graphic/143142.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Further guidance on the use of glucocorticoids, including setting treatment goals and dosing, is detailed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7976.html" rel="external">
          "Determinants of glucocorticoid dosing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H170227715">
         <span class="h2">
          Assessment for preexisting comorbid conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preexisting conditions that should be assessed for and treated when glucocorticoids are to be instituted include [
         <a href="#rid114">
          114
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes mellitus and prediabetes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poorly controlled hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart failure and peripheral edema
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity and overweight
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cataract or glaucoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peptic ulcer disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of infection, especially latent infections
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low bone density or osteoporosis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2223785618">
         <span class="h2">
          Use of preventive interventions
         </span>
        </p>
        <p class="headingAnchor" id="H1576007838">
         <span class="h3">
          Vaccine recommendations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who require an extended course of glucocorticoids should receive appropriate immunizations prior to the institution of therapy if clinically feasible; vaccination may vary based on the indication for glucocorticoid use. Vaccines for patients with autoimmune inflammatory rheumatic conditions are outlined in the following table  (
         <a class="graphic graphic_table graphicRef119665" href="/z/d/graphic/119665.html" rel="external">
          table 3
         </a>
         ). The immune response to vaccines may be compromised by glucocorticoid administration at doses of ≥20 mg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         . Recommendations for managing vaccinations in specific patient populations who may be taking glucocorticoids are described elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">
          "Immunizations in autoimmune inflammatory rheumatic disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">
          "Immunizations in hematopoietic cell transplant candidates and recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3899.html" rel="external">
          "Immunizations in adults with cancer"
         </a>
         .)
        </p>
        <p>
         The safety of live virus vaccines is described briefly below but is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3893.html" rel="external">
          "Measles, mumps, and rubella immunization in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">
          "Vaccination for the prevention of chickenpox (primary varicella infection)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8343.html" rel="external">
          "Vaccination for the prevention of shingles (herpes zoster)"
         </a>
         .)
        </p>
        <p>
         In general, live virus vaccines may be administered to patients who have taken:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         or its equivalent in doses of less than 20 mg/day for 14 days or less
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucocorticoids used for long-term physiologic replacement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucocorticoids administered topically, by aerosol, or by intraarticular or bursal injection, provided that there is no clinical or laboratory evidence of immunosuppression
        </p>
        <p>
        </p>
        <p>
         For patients taking 20 mg/day or more of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or its equivalent, the combination measles-mumps-rubella (MMR) vaccine and other live virus vaccines should not be administered for one month after the cessation of glucocorticoid therapy.
        </p>
        <p class="headingAnchor" id="H1413739347">
         <span class="h3">
          Prevention of opportunistic infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         As described above, it is well known that glucocorticoids are associated with an increased risk of infection (see
         <a class="local">
          'Immune system effects'
         </a>
         above). In some circumstances, the use of prophylaxis for an opportunistic infection with
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia (PJP) is recommended. However, this varies with the dose and duration of glucocorticoid therapy, as well as for the underlying disease being treated and concomitant immunosuppression (see appropriate topic reviews). We typically recommend PJP prophylaxis when glucocorticoids are given at doses above 20 mg/day for more than four weeks to patients who have another cause of immunocompromise. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Indications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2217532804">
         <span class="h3">
          Prevention of osteoporosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Depending on the length of the course of glucocorticoid treatment, osteoporosis prevention may be pursued at the start of therapy. Adequate dietary or supplementary calcium and vitamin D intake should be encouraged. Guidance for the prevention and treatment of glucocorticoid-induced osteoporosis is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2375038397">
         <span class="h3">
          Prevention of gastroduodenal toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who also require concomitant treatment with nonsteroidal antiinflammatory drugs (NSAIDs) or anticoagulants may require prophylaxis to prevent gastroduodenal toxicity. (See
         <a class="medical medical_review" href="/z/d/html/35.html" rel="external">
          "NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1137454963">
         <span class="h2">
          Monitoring and treatment of adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be routinely asked about adverse effects related to glucocorticoids. Intensity of monitoring will depend upon individual risk factors such as glucocorticoid dose and duration, other medications being used, and comorbidities. However, generally during treatment with glucocorticoids particular attention should be given to  (
         <a class="graphic graphic_table graphicRef143142" href="/z/d/graphic/143142.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid114">
          114
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – Patients on high-dose therapy should have screening for latent infections such as tuberculosis. Respiratory symptoms in patients on moderate- to high-dose glucocorticoids should also prompt consideration of workup for PJP pneumonia, especially if patients are on prolonged glucocorticoid courses with other immunosuppressive agents and/or are not taking prophylactic PJP therapy. (See
         <a class="medical medical_review" href="/z/d/html/8020.html" rel="external">
          "Tuberculosis infection (latent tuberculosis) in children", section on 'Immunosuppressed children'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osteoporosis
         </strong>
         – Patients who might require prolonged courses or high doses of glucocorticoids might benefit from screening for osteoporosis and consideration of treatment. (See
         <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">
          "Clinical features and evaluation of glucocorticoid-induced osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetes or glucose intolerance
         </strong>
         – Screening for glucose intolerance and type 2 diabetes may need to be intensified for patients on moderate- to high-dose glucocorticoids or on prolonged courses of low-dose therapy. Screening for type 2 diabetes is outlined in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">
          "Screening for type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When glucocorticoids induce symptomatic diabetes mellitus or asymptomatic but clinically significant hyperglycemia, these conditions are generally treated pharmacologically in the same way as for patients who are not on glucocorticoid therapy. Interestingly, a small phase 2 trial found that patients on continuous
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         for inflammatory diseases who were randomized to receive
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         demonstrated improvements in measures of metabolic activity as well as other clinical markers of disease activity compared with those receiving placebo [
         <a href="#rid115">
          115
         </a>
         ]. However, there is not enough data to recommend coadministration of metformin for patients taking glucocorticoids in the absence of another clinical indication to do so. (See
         <a class="medical medical_review" href="/z/d/html/5821.html" rel="external">
          "Management of type 2 diabetes mellitus in children and adolescents", section on 'Pharmacologic agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Glycemic management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cataracts or glaucoma
         </strong>
         – Patients on prolonged moderate- to high-dose therapy should be examined periodically by an ophthalmologist to promote early detection of cataracts and glaucoma. (See
         <a class="medical medical_review" href="/z/d/html/6909.html" rel="external">
          "Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis", section on 'Screening'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         There are several tools to measure glucocorticoid toxicity, including the Glucocorticoid Toxicity Index (GTI) in adults and the Pediatric Glucocorticoid Toxicity Index (pGTI) in children [
         <a href="#rid116">
          116-118
         </a>
         ]. These have primarily been used in clinical research, although they may be useful in clinical practice.
        </p>
        <p class="headingAnchor" id="H615562915">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120032.html" rel="external">
          "Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13921618">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83983.html" rel="external">
          "Patient education: Oral steroid medicines (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Factors related to glucocorticoid toxicity
         </strong>
         – The adverse effects of glucocorticoids are both dose- and duration-dependent. The effects of glucocorticoids are mediated by cytosolic glucocorticoid receptors and subsequent genomic and nongenomic mechanisms. Genetic polymorphisms in the glucocorticoid receptor and in glucocorticoid metabolism may explain heterogeneity in glucocorticoid toxicities observed. (See
         <a class="local">
          'Mechanisms of adverse effects'
         </a>
         above and
         <a class="local">
          'Glucocorticoid dose and duration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Organ-based toxicity
         </strong>
         – Glucocorticoids have adverse effects on many organ systems  (
         <a class="graphic graphic_table graphicRef65998" href="/z/d/graphic/65998.html" rel="external">
          table 1
         </a>
         ). Adverse effects range from those that are temporary but challenging for patients (eg, insomnia) to those that are life-threatening (eg, serious infections). Some adverse effects, such as accelerated reductions in bone mineral density or early cataracts, may be largely asymptomatic until later manifestations develop that require medical attention (eg, acute vertebral collapse, cataract requiring surgical extraction). The following organ systems can be affected by systemic glucocorticoids to varying degrees. (See
         <a class="local">
          'Organ-based toxicity of systemic glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Special populations
         </strong>
         – Certain populations may experience different complications from glucocorticoid use, including young children, menstruating females, and pregnant people. (See
         <a class="local">
          'Special populations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General treatment considerations and monitoring
         </strong>
         – We try to limit the adverse effects of glucocorticoids by taking the following steps (see
         <a class="local">
          'General treatment considerations and monitoring'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use the lowest dose of glucocorticoids for the shortest period of time needed to achieve the treatment goals
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Assess for preexisting comorbid conditions that may increase risk, and optimize the management of those conditions (see
         <a class="local">
          'Assessment for preexisting comorbid conditions'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use preventative interventions when available, including addressing appropriate immunization requirements, prevention of opportunistic infections, and prevention of osteoporosis (see
         <a class="local">
          'Use of preventive interventions'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monitor patients for adverse effects and pursue corrective interventions when possible  (
         <a class="graphic graphic_table graphicRef143142" href="/z/d/graphic/143142.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Monitoring and treatment of adverse effects'
         </a>
         above)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011; 63:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schäcke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007; 275:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramamoorthy S, Cidlowski JA. Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance. Endocr Dev 2013; 24:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker EH. Is there a safe and effective way to wean patients off long-term glucocorticoids? Br J Clin Pharmacol 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994; 21:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           W J Bijlsma J, Buttgereit F. Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies. Rheumatology (Oxford) 2016; 55:ii3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boers M, Hartman L, Opris-Belinski D, et al. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis 2022; 81:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review. Semin Arthritis Rheum 2016; 46:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003; 362:1828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol 1994; 30:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2015; 100:2171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carella MJ, Srivastava LS, Gossain VV, Rovner DR. Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy. J Clin Endocrinol Metab 1993; 76:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 2017; 357:j1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao TC, Huang YW, Chang SM, et al. Association Between Oral Corticosteroid Bursts and Severe Adverse Events : A Nationwide Population-Based Cohort Study. Ann Intern Med 2020; 173:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volkmann ER, Rezai S, Tarp S, et al. We still don't know how to taper glucocorticoids in rheumatoid arthritis, and we can do better. J Rheumatol 2013; 40:1646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988; 4:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shamoon H, Soman V, Sherwin RS. The influence of acute physiological increments of cortisol on fuel metabolism and insulin binding to monocytes in normal humans. J Clin Endocrinol Metab 1980; 50:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmons PS, Miles JM, Gerich JE, Haymond MW. Increased proteolysis. An effect of increases in plasma cortisol within the physiologic range. J Clin Invest 1984; 73:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoes JN, van der Goes MC, van Raalte DH, et al. Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011; 70:1887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu XX, Zhu XM, Miao Q, et al. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab 2014; 65:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 51:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmons LR, Molyneaux L, Yue DK, Chua EL. Steroid-induced diabetes: is it just unmasking of type 2 diabetes? ISRN Endocrinol 2012; 2012:910905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008; 58:2612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci 1976; 271:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch IB, Paauw DS. Diabetes management in special situations. Endocrinol Metab Clin North Am 1997; 26:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007; 157:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen Y, Pang Q, Xu J. Comprehensive pathogenesis and clinical therapy in striae distensae: An overview and current perspective. Clin J Plast Reconstr Surg 2022; 4:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mebrahtu TF, Morgan AW, West RM, et al. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ 2020; 192:E295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ajeganova S, Svensson B, Hafström I, BARFOT Study Group. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open 2014; 4:e004259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmowski A, Nielsen SM, Boyadzhieva Z, et al. The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis: Individual Patient Data From Five Randomized Trials. Ann Intern Med 2023; 176:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson SH, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci (Lond) 1981; 61 Suppl 7:381s.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitworth JA. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int Suppl 1992; 37:S34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saruta T, Suzuki H, Handa M, et al. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986; 62:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maradit Kremers H, Reinalda MS, Crowson CS, et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007; 57:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. PLoS Med 2020; 17:e1003432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aviña-Zubieta JA, Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013; 52:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           So H, Lam TO, Meng H, et al. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis 2023; 82:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006; 166:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huerta C, Lanes SF, García Rodríguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005; 16:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christiansen CF, Christensen S, Mehnert F, et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med 2009; 169:1677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akikusa JD, Feldman BM, Gross GJ, et al. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics 2007; 119:e778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majoor CJ, Kamphuisen PW, Zwinderman AH, et al. Risk of deep vein thrombosis and pulmonary embolism in asthma. Eur Respir J 2013; 42:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieber BA, Han J, Appelboom G, et al. Association of Steroid Use with Deep Venous Thrombosis and Pulmonary Embolism in Neurosurgical Patients: A National Database Analysis. World Neurosurg 2016; 89:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacLeod C, Hadoke PWF, Nixon M. Glucocorticoids: Fuelling the Fire of Atherosclerosis or Therapeutic Extinguishers? Int J Mol Sci 2021; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 53:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svenson KL, Lithell H, Hällgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987; 147:1917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacGregor AJ, Dhillon VB, Binder A, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992; 51:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strangfeld A, Richter A, Siegmund B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 2017; 76:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glenn F, Grafe WR Jr. Surgical complications of adrenal steroid therapy. Ann Surg 1967; 165:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterioff S, Orringer MB, Cameron JL. Colon perforations associated with steroid therapy. Surgery 1974; 75:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mpofu S, Mpofu CM, Hutchinson D, et al. Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis 2004; 63:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie F, Yun H, Bernatsky S, Curtis JR. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Arthritis Rheumatol 2016; 68:2612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones JP Jr, Engleman EP, Najarian JS. Systemic fat embolism after renal homotransplantation and treatment with corticosteroids. N Engl J Med 1965; 273:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HILL LW. Certain aspects of allergy in children. A critical review of the recent literature. N Engl J Med 1961; 265:1298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dourakis SP, Sevastianos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 2002; 97:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CARONE FA, LIEBOW AA. Acute pancreatic lesions in patients treated with ACTH and adrenal corticoids. N Engl J Med 1957; 257:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA 1993; 269:2110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadr-Azodi O, Mattsson F, Bexlius TS, et al. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Intern Med 2013; 173:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derk CT, DeHoratius RJ. Systemic lupus erythematosus and acute pancreatitis: a case series. Clin Rheumatol 2004; 23:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saab S, Corr MP, Weisman MH. Corticosteroids and systemic lupus erythematosus pancreatitis: a case series. J Rheumatol 1998; 25:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolkowitz OM, Burke H, Epel ES, Reus VI. Glucocorticoids. Mood, memory, and mechanisms. Ann N Y Acad Sci 2009; 1179:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown ES, Chandler PA. Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion J Clin Psychiatry 2001; 3:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry 2012; 169:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 2011; 33:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaikh S, Verma H, Yadav N, et al. Applications of steroid in clinical practice: A review. Int Sch Res Notices 2012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolanos SH, Khan DA, Hanczyc M, et al. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol 2004; 92:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swinburn CR, Wakefield JM, Newman SP, Jones PW. Evidence of prednisolone induced mood change ('steroid euphoria') in patients with chronic obstructive airways disease. Br J Clin Pharmacol 1988; 26:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown ES, Suppes T, Khan DA, Carmody TJ 3rd. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol 2002; 22:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology 1988; 38:1631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996; 21:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972; 13:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubovsky AN, Arvikar S, Stern TA, Axelrod L. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics 2012; 53:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 1989; 30:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology 2003; 61:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin SY, Katz P, Wallhagen M, Julian L. Cognitive impairment in persons with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keenan PA, Jacobson MW, Soleymani RM, et al. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996; 47:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WALKER AE, ADAMKIEWICZ JJ. PSEUDOTUMOR CEREBRI ASSOCIATED WITH PROLONGED CORTICOSTEROID THERAPY. REPORTS OF FOUR CASES. JAMA 1964; 188:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black RL, Oglesby RB, von Sallmann L, Bunim JJ. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960; 174:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkowitz JS, David DS, Sakai S, et al. Ocular complications in renal transplant recipients. Am J Med 1973; 55:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skalka HW, Prchal JT. Effect of corticosteroids on cataract formation. Arch Ophthalmol 1980; 98:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long WF. A case of elevated intraocular pressure associated with systemic steroid therapy. Am J Optom Physiol Opt 1977; 54:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slansky HH, Kolbert G, Gartner S. Exophathalmos induced by steroids. Arch Ophthalmol 1967; 77:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crews SJ. Adverse Reactions to Corticosteroid Therapy in the Eye. Proc R Soc Med 1965; 58:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Nijs E, Brabant P, De Laey JJ. The adverse effects of corticosteroids in central serous chorioretinopathy. Bull Soc Belge Ophtalmol 2003; :35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004; 111:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karadimas P, Kapetanios A, Bouzas EA. Central serous chorioretinopathy after local application of glucocorticoids for skin disorders. Arch Ophthalmol 2004; 122:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma T, Shah N, Rao M, et al. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 2004; 111:1708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306:2331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Migita K, Arai T, Ishizuka N, et al. Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy. PLoS One 2013; 8:e78699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George MD, Baker JF, Winthrop K, et al. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. Ann Intern Med 2020; 173:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012; 71:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 1999; 246:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang S, Shi M, Bai Y, et al. The effect of glucocorticoids on serum cystatin C in identifying acute kidney injury: a propensity-matched cohort study. BMC Nephrol 2020; 21:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoji N, Endo Y, Iikubo M, et al. Dentin hypersensitivity-like tooth pain seen in patients receiving steroid therapy: An exploratory study. J Pharmacol Sci 2016; 132:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mens JM, Nico de Wolf A, Berkhout BJ, Stam HJ. Disturbance of the menstrual pattern after local injection with triamcinolone acetonide. Ann Rheum Dis 1998; 57:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pernicova I, Kelly S, Ajodha S, et al. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes Endocrinol 2020; 8:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brogan P, Naden R, Ardoin SP, et al. The pediatric glucocorticoid toxicity index. Semin Arthritis Rheum 2022; 56:152068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miloslavsky EM, Naden RP, Bijlsma JW, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis 2017; 76:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JH, McDowell PJ, Jayne DRW, et al. The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time. Semin Arthritis Rheum 2022; 55:152010.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7988 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12441176" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Mechanisms involved in the side effects of glucocorticoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20936628" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Exogenous and endogenous glucocorticoids in rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17630119" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23392094" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33289121" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Is there a safe and effective way to wean patients off long-term glucocorticoids?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18684744" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Dose-related patterns of glucocorticoid-induced side effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8109596" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7966059" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16739208" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Population-based assessment of adverse events associated with long-term glucocorticoid use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16107513" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27856654" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35641125" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27105755" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14654323" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Glucocorticoids and invasive fungal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8176017" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25844620" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8388401" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28404617" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32628532" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Association Between Oral Corticosteroid Bursts and Severe Adverse Events : A Nationwide Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24085754" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : We still don't know how to taper glucocorticoids in rheumatoid arthritis, and we can do better.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3278872" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effects of glucocorticoids on carbohydrate metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6987255" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The influence of acute physiological increments of cortisol on fuel metabolism and insulin binding to monocytes in normal humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6365973" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Increased proteolysis. An effect of increases in plasma cortisol within the physiologic range.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21908880" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Glucose tolerance, insulin sensitivity andβ-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25402408" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1994531" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22830041" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Steroid-induced diabetes: is it just unmasking of type 2 diabetes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18759273" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/178180" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effects of glucocorticoids on carbohydrate metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8267494" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Glucocorticoids and the risk for initiation of hypoglycemic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9314019" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Diabetes management in special situations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8239251" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17501951" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Comprehensive pathogenesis and clinical therapy in striae distensae: An overview and current perspective
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15545676" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3298796" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Mechanisms of glucocorticoid-induced hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32392512" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18077493" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24710131" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37579312" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis: Individual Patient Data From Five Randomized Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6797777" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Does long-term low-dose corticosteroid therapy cause hypertension?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1321309" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Adrenocorticotrophin and steroid-induced hypertension in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3510223" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15253953" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17330277" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33270649" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23192907" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37487608" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16682576" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Corticosteroids and the risk of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15824553" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Respiratory medications and the risk of cardiac arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19822824" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17308245" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Sinus bradycardia after intravenous pulse methylprednisolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23258790" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Risk of deep vein thrombosis and pulmonary embolism in asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26805689" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Association of Steroid Use with Deep Venous Thrombosis and Pulmonary Embolism in Neurosurgical Patients: A National Database Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34299240" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Glucocorticoids: Fuelling the Fire of Atherosclerosis or Therapeutic Extinguishers?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12922956" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16082633" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3675092" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1522805" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7966068" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Lipid profiles in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1550394" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6343871" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Association of adrenocorticosteroid therapy and peptic-ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2012355" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1834002" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27405509" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4290718" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Surgical complications of adrenal steroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4808723" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Colon perforations associated with steroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15082493" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27213279" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5322324" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Systemic fat embolism after renal homotransplantation and treatment with corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13907365" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Certain aspects of allergy in children. A critical review of the recent literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12003403" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Acute severe steatohepatitis related to prednisolone therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22326434" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13477372" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Acute pancreatic lesions in patients treated with ACTH and adrenal corticoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8468765" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440105" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15045630" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Systemic lupus erythematosus and acute pancreatitis: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9558190" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Corticosteroids and systemic lupus erythematosus pancreatitis: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19906230" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Glucocorticoids. Mood, memory, and mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15014624" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Mood and Cognitive Changes During Systemic Corticosteroid Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22764363" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21999885" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Applications of steroid in clinical practice: A review
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15191017" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3242575" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Evidence of prednisolone induced mood change ('steroid euphoria') in patients with chronic obstructive airways disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11799343" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Mood changes during prednisone bursts in outpatients with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2843795" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8778901" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5053810" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Acute adverse reactions to prednisone in relation to dosage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22424158" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2652177" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Psychiatric side effects of steroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12847167" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22505279" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Cognitive impairment in persons with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8960717" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The effect on memory of chronic prednisone treatment in patients with systemic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14132530" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : PSEUDOTUMOR CEREBRI ASSOCIATED WITH PROLONGED CORTICOSTEROID THERAPY. REPORTS OF FOUR CASES.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13801171" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4582704" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Ocular complications in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7425901" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Effect of corticosteroids on cataract formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/143890" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : A case of elevated intraocular pressure associated with systemic steroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6022727" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Exophathalmos induced by steroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19994429" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Adverse Reactions to Corticosteroid Therapy in the Eye.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14619628" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : The adverse effects of corticosteroids in central serous chorioretinopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15019370" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Risk factors for central serous chorioretinopathy: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15136332" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Central serous chorioretinopathy after local application of glucocorticoids for skin disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15350327" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22056398" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Initiation of tumor necrosis factor-αantagonists and the risk of hospitalization for infection in patients with autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24260127" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32956604" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22241902" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10475992" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33246435" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : The effect of glucocorticoids on serum cystatin C in identifying acute kidney injury: a propensity-matched cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27842970" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Dentin hypersensitivity-like tooth pain seen in patients receiving steroid therapy: An exploratory study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9924216" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Disturbance of the menstrual pattern after local injection with triamcinolone acetonide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17660219" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32109422" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35917759" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : The pediatric glucocorticoid toxicity index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27474764" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35486995" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
